Advanced Prostate Cancer Treatments: From Hormone Therapy to CAR-T and Radioligand Therapy

Explore cutting-edge therapies for prostate cancer including AR inhibitors, chemotherapy, immunotherapy, PARP inhibitors, radioligand therapy, and emerging ADCs and CAR-T.

Hormonal and Androgen-Directed Therapies

Abiraterone acetate inhibits CYP17 to block androgen biosynthesis, improving overall survival in both metastatic hormone-sensitive and castration-resistant prostate cancer. It is typically combined with ADT and prednisone. Enzalutamide, an androgen receptor inhibitor, enhances radiographic progression-free survival and overall survival and is used with ADT. Both are FDA-approved guideline standards.

Abiraterone Acetate

Target: CYP17 inhibition. Benefits: Proven survival improvement in mHSPC and mCRPC. Combinations: ADT, prednisone. Status: FDA-approved, standard of care.

Enzalutamide

Target: Androgen receptor inhibitor. Benefits: Improves rPFS and OS. Combinations: ADT. Status: FDA-approved, standard of care.

Chemotherapy Options

Docetaxel, a microtubule-inhibiting cytotoxic, is first-line chemotherapy that extends survival in metastatic hormone-sensitive and castration-resistant disease. It may follow AR-targeted therapy. Cabazitaxel, effective after docetaxel failure, improves survival in docetaxel-resistant mCRPC. Both are FDA-approved: docetaxel as first-line chemo, cabazitaxel as second-line standard.

Docetaxel

Target: Microtubule inhibition. Benefits: First-line chemo, improves survival in mHSPC and mCRPC. Combinations: ADT or after AR-targeted therapy. Status: FDA-approved, guideline standard.

Cabazitaxel

Target: Microtubule inhibition (post-docetaxel). Benefits: Improves survival in docetaxel-resistant mCRPC. Combinations: Often used post-docetaxel. Status: FDA-approved, second-line standard.

Immunotherapy and Targeted Therapies

Sipuleucel-T is an autologous dendritic cell immunotherapy that provides modest survival benefit for asymptomatic or minimally symptomatic mCRPC. PARP inhibitors (e.g., olaparib) target homologous recombination repair defects (BRCA1/2, ATM) and improve progression-free survival in HRR-mutated mCRPC. Radioligand therapy with 177Lu-PSMA-617 delivers targeted radiation to PSMA-positive cells, improving overall survival and quality of life in PSMA-positive mCRPC. These FDA-approved options represent key advances in precision medicine.

Sipuleucel-T

Target: Autologous dendritic cell immunotherapy. Benefits: Modest survival improvement in asymptomatic/minimally symptomatic mCRPC. Combinations: None routinely. Status: FDA-approved, limited availability.

PARP Inhibitors (Olaparib)

Target: HRR repair defects (BRCA1/2, ATM). Benefits: Improves PFS in HRR-mutated mCRPC. Combinations: Can combine with AR-directed therapy depending on mutation. Status: FDA-approved for HRR-mutated PCa.

Radioligand Therapy (177Lu-PSMA-617)

Target: PSMA-targeted radioactive ligand. Benefits: Improves OS and quality of life in PSMA-positive mCRPC. Combinations: Being studied with AR agents. Status: FDA-approved (2022+), active trials for combinations.

Emerging Approaches

Antibody-drug conjugates (ADCs) target tumor antigens such as TROP-2 and STEAP1 to deliver cytotoxic payloads, but no ADC is yet approved for prostate cancer; they remain in clinical trials. CAR-T cell therapy engineers T-cells to target PSMA or STEAP1 antigens, showing promise in preclinical and early-phase trials but not yet FDA-approved. Both fields are actively investigated for future breakthroughs.

Antibody-Drug Conjugates (ADCs)

Target: Tumor antigens (TROP-2, STEAP1). Benefits: Early trials only; no approved ADCs yet. Combinations: Under evaluation. Status: Clinical trials only.

CAR-T Cell Therapy

Target: Engineered T-cells targeting PCa antigens (PSMA, STEAP1). Benefits: Preclinical and early-phase trials show promise. Combinations: Experimental. Status: Not FDA-approved; research stage.